Neuregulin-ERBB Signaling in the Nervous System and Neuropsychiatric Diseases

Mei, Lin; Nave, Klaus-Armin

doi:10.1016/j.neuron.2014.06.007

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Neuregulin-ERBB Signaling in the Nervous System and Neuropsychiatric Diseases

MPS-Authors

/persons/resource/persons182320

Nave, Klaus-Armin
Neurogenetics, Max Planck Institute of Experimental Medicine, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Mei, L., & Nave, K.-A. (2014). Neuregulin-ERBB Signaling in the Nervous System and Neuropsychiatric Diseases. Neuron, 83(1), 27-49. doi:10.1016/j.neuron.2014.06.007.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002A-F1A0-A

Abstract

Neuregulins (NRGs) comprise a large family of growth factors that stimulate ERBB receptor tyrosine kinases. NRGs and their receptors, ERBBs, have been identified as susceptibility genes for diseases such as schizophrenia (SZ) and bipolar disorder. Recent studies have revealed complex Nrg/Erbb signaling networks that regulate the assembly of neural circuitry, myelination, neurotransmission, and synaptic plasticity. Evidence indicates there is an optimal level of NRG/ERBB signaling in the brain and deviation from it impairs brain functions. NRGs/ERBBs and downstream signaling pathways may provide therapeutic targets for specific neuropsychiatric symptoms.